One - Year Survival Analysis And TCM Syndromes Analysis Of HBV - Associated Primary Liver Cancer With PVTT

Objective:1 Through to hepatitis B virus associated primary hepatocellular carcinoma with portal vein thrombosis in patients with clinical data were reviewed of investigation, statistics, analysis and summarize the clinical hepatitis B virus associated primary hepatocellular carcinoma with portal vein thrombosis 1 year survival factors.2 To evaluate the hepatitis B virus associated primary hepatocellular carcinoma with portal vein embolism in patients with TCM syndrome type "Yin deficiency type and non Yin deficiency type clinical features.Method:1 According to the inclusion criteria, into the group of hepatitis B virus associated primary hepatocellular carcinoma with portal vein embolization of 173 patients with, clinical data were collected:age, sex, laboratory refers to (liver function, blood coagulation function, blood routine, hepatitis B, hepatitis B virus load, tumor learn markers, lymphocyte count), imaging indexes (portal vein tumor thrombus location). Statistical analysis the risk factors for survival.2 According to the inclusion criteria, original group of primary liver cancer complicated with portal vein thrombosis in patients with Yin deficiency type in 27 cases,18 cases of non Yin deficiency type, clinical data were collected:age, sex, laboratory refers to (liver function, blood coagulation function, blood routine, hepatitis B, hepatitis B virus load, oncology standard markers, lymphocyte count), imaging indexes (portal vein tumor thrombus parts) and analysis the difference of statistical survival time in both groups.Results:1 HBV related form primary hepatocellular carcinoma with PVTT 173 cases and analysis of general information, more men than women, male to female ratio for 5.18:1. Patients age minimum for 28 years old, the oldest is 79 year old, average morbidity age 55.61+10.17 years,51-60 years old more patients.173,2 Cases of HBV associated primary liver cancer patients with PVTT,1 patients died in 121 years,52 cases of survival, survival rate was 42.98%. Baseline characteristics were compared between the two groups. It was found that the two groups of patients with tumor thrombus location, WBC, alt, AST, TBIL, ALP, GGT, ALP, Che, GLB and a/g, NH3, CD4+T/CD8+T, AFP, HBV DNA, minimally invasive treatment, ascites had significant difference.3 The cumulative survival analysis parts of tumor thrombus in the left and right main/principal left/right, AFP (less than or equal to 1000ng/ml) and HBV DNA (less than or equal to 500copies/L), minimally invasive treatment of intermediary in the RF+ and no ascites patient survival rate is high. WBC< 5.13 x 109/L, ALT is less than or equal to 32U/L, DBIL is less than or equal to 8.7umol/L, GGT is less than or equal to 71.45U/L, ALP is less than or equal to 117.05U/L, GLB is less than or equal to 30.75g/L in patients with survival rate is high. And CD4+T/, CD8+T CHE survival rate had no effect.4 HBV related form of primary hepatocellular carcinoma with PVTT 173 patients with Cox univariate analysis:treatment, white blood cells, alt, TBIL, glo, GGT, ALP, Che, Pt, HBVDNA, AFP, ascites and survival rate were positively correlated, location and survival of tumor thrombus was negative correlation. Multivariate analysis showed that TBA, HBVDNA, AFP, ascites were positively correlated with survival.5 COX regression equation PI= TBA*0.711+0.006* HBVDNA (positive for 1, negative for 0)+AFP*0.581 (positive for 1, negative for 0)+0.619* ascites (positive for 1, negative for 0). Prediction of HBV related primary liver cancer patients with PVTT 1 years survival, PI model diagnosis than the MELD score and any individual indicators higher. The area under the ROC curve was 0.781,0.615,0.672,0.623,0.694, 0.616.6 Forecast PI=1.09, HBV related primary liver cancer with PVTT 1 year survival of patients to achieve the average survival rate, PI< 1.09 patients 1 year survival rate is low, PI> 109 patients 1 year survival rate is high, two groups compare P< 0.001.7 HBV related primary liver cancer patients with PVTT in patients with non Yin deficiency group and yin deficiency group Cr have statistical significance, P=0.03.8 The CR set cut-off value found, Cr> 76.95 mol/L and Cr is less than or equal to 76.95 mol/L compared survival rate no difference (P=0.091). Non Yin deficiency group CR> 76.95 mol/L and Cr is less than or equal to 76.95umol/L survival rate had no significant difference (P=0.322), and yin deficiency group in CR is less than or equal to 76.95 mol/L than CR> 76.95 umol/L survival rate high (P=0.006).Conclusions:1 HBV related primary liver cancer patients with PVTT were affected by TBA, HBVDNA, AFP, ascites and AFP in 1 years.2 Prediction of HBV related primary liver cancer patients with PVTT 1 years survival of the COX risk ratio regression model for PI= TBA*0.711+0.006* HBVDNA (positive for 1, negative for 0)+AFP*0.581 (positive for 1, negative for 0) +0.619* ascites (positive for 1, negative for 0), the patients studied had an average survival rate, PI< 1.09 of patients with a low survival rate of 1 years, PI> 1.09 of patients with a high survival rate of 1 years.3 Prediction of HBV related primary liver cancer patients with PI 1 years survival PVTT model is better than the MELD score, the area under the ROC curve was 0.781 and 0.615.4 HBV related primary hepatocellular cancer with PVTT group patients with deficiency of Cr is lower than that of non Yin deficiency group; Yin deficiency group when CR was smaller survival rate of higher and higher.